Free Trial

Digital Health Acquisition (DHAC) Competitors

Digital Health Acquisition logo
$0.72 +0.02 (+2.27%)
As of 09/11/2025

DHAC vs. BGLC, SSY, ACON, VSEE, NIVF, BACK, OTRK, BTTX, UPHL, and OPGN

Should you be buying Digital Health Acquisition stock or one of its competitors? The main competitors of Digital Health Acquisition include BioNexus Gene Lab (BGLC), SunLink Health Systems (SSY), Aclarion (ACON), VSee Health (VSEE), NewGenIvf Group (NIVF), IMAC (BACK), Ontrak (OTRK), Better Therapeutics (BTTX), UpHealth (UPHL), and OpGen (OPGN). These companies are all part of the "healthcare" industry.

Digital Health Acquisition vs. Its Competitors

Digital Health Acquisition (NASDAQ:DHAC) and BioNexus Gene Lab (NASDAQ:BGLC) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Digital Health Acquisition has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, BioNexus Gene Lab has a beta of 5.31, suggesting that its share price is 431% more volatile than the S&P 500.

Digital Health Acquisition has a net margin of 0.00% compared to BioNexus Gene Lab's net margin of -30.70%. Digital Health Acquisition's return on equity of 0.00% beat BioNexus Gene Lab's return on equity.

Company Net Margins Return on Equity Return on Assets
Digital Health AcquisitionN/A N/A N/A
BioNexus Gene Lab -30.70%-35.54%-29.08%

Digital Health Acquisition has higher earnings, but lower revenue than BioNexus Gene Lab.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Digital Health AcquisitionN/AN/AN/AN/AN/A
BioNexus Gene Lab$9.51M1.03-$1.60MN/AN/A

In the previous week, Digital Health Acquisition and Digital Health Acquisition both had 1 articles in the media. BioNexus Gene Lab's average media sentiment score of 1.91 beat Digital Health Acquisition's score of 0.00 indicating that BioNexus Gene Lab is being referred to more favorably in the news media.

Company Overall Sentiment
Digital Health Acquisition Neutral
BioNexus Gene Lab Very Positive

1.0% of Digital Health Acquisition shares are owned by institutional investors. Comparatively, 18.9% of BioNexus Gene Lab shares are owned by institutional investors. 6.6% of Digital Health Acquisition shares are owned by company insiders. Comparatively, 0.7% of BioNexus Gene Lab shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Digital Health Acquisition and BioNexus Gene Lab tied by winning 4 of the 8 factors compared between the two stocks.

Get Digital Health Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for DHAC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DHAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DHAC vs. The Competition

MetricDigital Health AcquisitionHolding Offices IndustryServices SectorNASDAQ Exchange
Market Cap$2.60M$214.90M$1.13B$10.15B
Dividend YieldN/A3.15%5.94%4.60%
P/E RatioN/A0.173.7825.92
Price / SalesN/A437.882.0885.33
Price / CashN/A123.70191.7559.91
Price / BookN/A7.064.056.29
Net IncomeN/A-$11.59M-$25.89M$270.77M
7 Day Performance7.63%-1.74%2.77%3.36%
1 Month Performance-45.38%-3.18%-1.87%6.41%
1 Year Performance-57.34%165.65%-22.48%28.24%

Digital Health Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DHAC
Digital Health Acquisition
N/A$0.72
+2.3%
N/A-60.4%$2.60MN/A0.002,021News Coverage
Gap Up
BGLC
BioNexus Gene Lab
0.6313 of 5 stars
$4.88
+13.4%
N/A+21.4%$8.78M$9.51M0.0030Positive News
Gap Up
High Trading Volume
SSY
SunLink Health Systems
N/A$1.12
+16.6%
N/A+48.2%$7.88M$31.09M4.661,376Gap Up
ACON
Aclarion
2.5885 of 5 stars
$7.43
-0.3%
$11,758.50
+158,157.1%
-99.5%$4.31M$50K0.007Positive News
VSEE
VSee Health
1.8632 of 5 stars
$0.71
-2.2%
$5.00
+609.2%
-57.3%$2.54M$10.42M0.00N/AShort Interest ↓
Gap Down
NIVF
NewGenIvf Group
N/A$2.02
-2.9%
N/A-99.7%$1.74M$5.43M0.00N/APositive News
BACK
IMAC
N/A$0.08
-3.4%
N/A-95.0%$160K$72.05K0.00180Gap Up
OTRK
Ontrak
2.9585 of 5 stars
$0.02
-33.8%
$3.00
+13,821.1%
-99.0%$91K$10.18M0.00250Short Interest ↓
Gap Down
BTTX
Better Therapeutics
N/A$0.00
flat
N/AN/A$5KN/A0.0040
UPHL
UpHealth
N/A$0.00
flat
N/A-99.9%$4K$130M0.001,750
OPGN
OpGen
N/AN/AN/AN/A$1K$2.67M0.00100Positive News
Short Interest ↓

Related Companies and Tools


This page (NASDAQ:DHAC) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners